Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosapride and Medirac in IBS Without Diarrhea
NCT01505777Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mosapride in irritable bowel syndrome (IBS) (5 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from Baseline in patient's overall satisfaction relief at 4 weeks. Started May 2011; status: completed.
02
Drugs
mosapride
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT01505777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505777.